Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UniCAR02-T plus TM123 in CD123-positive hematologic malignancies
NL-OMON53976Phase 1Recruiting
- Sponsor
- AvenCell Therapeutics
- Start
- Jan 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of UniCAR02-T and TM123 in acute myeloid leukemia (AML) and Blastic plasmacytoid dendritic cell neoplasm (BPDCN) (4 arms), sponsored by AvenCell Therapeutics. Primary endpoints: Safety and tolerability, Incidence of dose-limiting toxicities and 3 more. Started Jan 2024; status: recruiting.
02
Drugs
UniCAR02-TTM123
03
Conditions
acute myeloid leukemia (AML)Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Beyond the preview
Go deeper on NL-OMON53976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53976.